MorphoSys Sustainability Profile
MorphoSys AG, a leading biopharmaceutical company headquartered in Germany, is renowned for its innovative approach in the field of therapeutic antibodies. Founded in 1992, the company has made significant strides in the development of treatments for cancer and autoimmune diseases, establishing a strong presence in Europe and North America. With a focus on proprietary and partnered drug development, MorphoSys has achieved notable milestones, including the successful launch of its flagship product, Monjuvi (tafasitamab), which targets specific forms of lymphoma. The company’s unique technology platforms, such as its Ylanthus® antibody library, enable the rapid discovery of high-quality therapeutic candidates, positioning MorphoSys as a key player in the biopharmaceutical industry. Through its commitment to advancing healthcare, MorphoSys continues to make impactful contributions to patient care and treatment options.
DitchCarbon Score
How does MorphoSys's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
MorphoSys's score of 76 is higher than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
MorphoSys's reported carbon emissions
In 2023, MorphoSys reported total carbon emissions of approximately 18,856,470 kg CO2e. This figure includes Scope 1 emissions of about 101,820 kg CO2e, Scope 2 emissions of approximately 1,340 kg CO2e, and significant Scope 3 emissions amounting to about 18,753,310 kg CO2e. The Scope 3 emissions are primarily driven by capital goods (approximately 10,204,310 kg CO2e) and business travel (around 1,833,700 kg CO2e). MorphoSys has not set specific reduction targets or initiatives as per the latest data, and there are no climate pledges reported. The emissions data is cascaded from its parent company, Novartis AG, reflecting a corporate family relationship that influences its climate commitments and reporting practices. Overall, MorphoSys's emissions profile highlights the importance of addressing Scope 3 emissions, which constitute the majority of its carbon footprint, while the absence of defined reduction targets suggests an area for potential improvement in their climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 10,335,000 | 000,000 |
| Scope 2 | 1,060.64 | 0,000 |
| Scope 3 | 1,072.96 | 00,000,000 |
How Carbon Intensive is MorphoSys's Industry?
How Carbon Intensive is MorphoSys's Location?
MorphoSys's Scope 3 Categories Breakdown
MorphoSys's Scope 3 emissions, which increased significantly last year and increased significantly since 2022, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Capital Goods" being the largest emissions source at 54% of Scope 3 emissions.
Top Scope 3 Categories
MorphoSys's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
MorphoSys has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.